메뉴 건너뛰기




Volumn 18, Issue 4, 2010, Pages 213-217

Saxagliptin: A new dipeptidyl peptidase-4 inhibitor for type 2 diabetes

Author keywords

Diabetes; Dipeptidyl peptidase 4 enzyme inhibitors; Incretins; Saxagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIGOXIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; 2,4-THIAZOLIDINEDIONE; ADAMANTANE; DIPEPTIDE; SULFONYLUREA DERIVATIVE;

EID: 77953998497     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181daad5f     Document Type: Review
Times cited : (12)

References (19)
  • 1
    • 84866761034 scopus 로고    scopus 로고
    • November, Available at Accessed November 28, 2009
    • World Health Organization. Diabetes: fact sheet (no.312). November 2009. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed November 28, 2009.
    • (2009) Diabetes: Fact Sheet (no.312)
  • 2
    • 61349099439 scopus 로고    scopus 로고
    • Diagnosis and classification of diabetes mellitus
    • American Diabetes Association
    • American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(Suppl 1):S62-S67.
    • (2009) Diabetes Care , vol.32 , Issue.SUPPL. 1
  • 3
    • 60449089649 scopus 로고    scopus 로고
    • American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
    • (2009) Diabetes Care , vol.32 , pp. 193-203
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3
  • 4
    • 84925564345 scopus 로고    scopus 로고
    • Onglyza -package insert-. Princeton, NJ: Bristol-Myers Squibb Company, 2009
    • Onglyza -package insert-. Princeton, NJ: Bristol-Myers Squibb Company; 2009.
  • 5
    • 34248223285 scopus 로고    scopus 로고
    • Biology of incretins: GLP-1 and GIP
    • Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-2157.
    • (2007) Gastroenterology , vol.132 , pp. 2131-2157
    • Baggio, L.L.1    Drucker, D.J.2
  • 6
    • 33845344395 scopus 로고
    • Plasma insulin response to oral and intravenous glucose administration
    • Elrick H, Stimmler L, Hlad CJ Jr, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1966;24:1076-1082.
    • (1966) J Clin Endocrinol Metab , vol.24 , pp. 1076-1082
    • Elrick, H.1    Stimmler, L.2    Hlad Jr., C.J.3
  • 7
    • 0142258657 scopus 로고    scopus 로고
    • Gut peptides and type 2 diabetes mellitus treatment
    • Ahren B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep. 2003;3:365-372.
    • (2003) Curr Diab Rep , vol.3 , pp. 365-372
    • Ahren, B.1
  • 8
    • 0022461548 scopus 로고
    • Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
    • Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocr Rev. 1986;63:492-498.
    • (1986) J Clin Endocr Rev , vol.63 , pp. 492-498
    • Ma, N.1    Homberger, E.2    Siegel, E.G.3
  • 9
    • 0037312818 scopus 로고    scopus 로고
    • Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis
    • Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003;17:161-171.
    • (2003) Mol Endocrinol , vol.17 , pp. 161-171
    • Drucker, D.J.1
  • 10
    • 0034838323 scopus 로고    scopus 로고
    • Glucose-dependent insulinotropic polypeptide is a growth factor for beta cells by pleiotropic signaling
    • Trumper A, Trumper K, Trusheim H, et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta cells by pleiotropic signaling. Mol Endocrinol. 2001;15:1559-1570.
    • (2001) Mol Endocrinol , vol.15 , pp. 1559-1570
    • Trumper, A.1    Trumper, K.2    Trusheim, H.3
  • 11
    • 0033520869 scopus 로고    scopus 로고
    • GIP biology and fat metabolism
    • Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci. 2000;66:91-103.
    • (2000) Life Sci , vol.66 , pp. 91-103
    • Yip, R.G.1    Wolfe, M.M.2
  • 12
    • 0028953577 scopus 로고
    • Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolites in vivo
    • Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolites in vivo. J Clin Endocrinol Metab. 1995;80:952-957.
    • (1995) J Clin Endocrinol Metab , vol.80 , pp. 952-957
    • Deacon, C.F.1    Johnsen, A.H.2    Holst, J.J.3
  • 13
    • 0033619675 scopus 로고    scopus 로고
    • Dipeptidyl-peptidase IV (CD 26)-role in the inactivation of regulatory peptides
    • Mentlein R. Dipeptidyl-peptidase IV (CD 26) -role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9-24.
    • (1999) Regul Pept , vol.85 , pp. 9-24
    • Mentlein, R.1
  • 14
    • 73449117555 scopus 로고    scopus 로고
    • Saxagliptin: A new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
    • Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009;26:249-262.
    • (2009) Adv Ther , vol.26 , pp. 249-262
    • Tahrani, A.A.1    Piya, M.K.2    Barnett, A.H.3
  • 15
    • 70349333861 scopus 로고    scopus 로고
    • CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
    • Rosenstock J, Aguilar-Salinas C, Klein E, et al. CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin. 2009;25:2401-2411.
    • (2009) Curr Med Res Opin , vol.25 , pp. 2401-2411
    • Rosenstock, J.1    Aguilar-Salinas, C.2    Klein, E.3
  • 16
    • 68949212458 scopus 로고    scopus 로고
    • Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomized controlled trial
    • Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial. Int J Clin Pract. 2009;63:1395-1406.
    • (2009) Int J Clin Pract , vol.63 , pp. 1395-1406
    • Chacra, A.R.1    Tan, G.H.2    Apanovitch, A.3
  • 17
    • 69549135336 scopus 로고    scopus 로고
    • The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone
    • Defronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009;32: 1649-1655.
    • (2009) Diabetes Care , vol.32 , pp. 1649-1655
    • Defronzo, R.A.1    Hissa, M.N.2    Garber, A.J.3
  • 18
    • 65549123794 scopus 로고    scopus 로고
    • Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial
    • Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611-622.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 611-622
    • Jadzinsky, M.1    Pfutzner, A.2    Paz-Pacheco, E.3
  • 19
    • 73149084956 scopus 로고    scopus 로고
    • For the CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone
    • Hollander P, Li J, Allen E, et al; for the CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94:4810-4819.
    • (2009) J Clin Endocrinol Metab , vol.94 , pp. 4810-4819
    • Hollander, P.1    Li, J.2    Allen, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.